aTYR PHARMA (ATYR) Accounts Payables (2014 - 2026)

aTYR PHARMA (ATYR) has reported Accounts Payables for 13 consecutive years, with $3.2 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Accounts Payables fell 16.46% year-over-year to $3.2 million; the trailing twelve-month figure through Jun 2026 stood at $3.2 million (down 16.46% YoY), and the FY2025 full-year result was $3.9 million, down 9.99% from the prior year.
• Accounts Payables climbed to $3.2 million in Q2 2026 per ATYR's latest filing, from $2.8 million in the prior quarter.
• Across five years, Accounts Payables topped out at $4.9 million in Q1 2024 and bottomed at $516000.0 in Q2 2023.
• Historically, Accounts Payables has averaged $3.0 million across 5 years, with a median of $3.2 million in 2022.
• The sharpest annual moves came in 2022 and 2023: Accounts Payables soared 247.67% in 2022, then plunged 69.18% in 2023.
• Over 5 years, Accounts Payables stood at $3.1 million in 2022, then grew by 13.62% to $3.5 million in 2023, then advanced by 22.5% to $4.3 million in 2024, then retreated by 9.99% to $3.9 million in 2025, then dropped by 16.68% to $3.2 million in 2026.
• According to Business Quant data, Accounts Payables over the past three periods registered $3.2 million, $2.8 million, and $3.9 million for Q2 2026, Q1 2026, and Q4 2025 respectively.